PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 402, Issue 2, 2010, Pages 345-350

  Russo, Debora ^a   Ottaggio, Laura ^a   Penna, Ilaria ^a   Foggetti, Giorgia ^a   Fronza, Gilberto ^a   Inga, Alberto ^b   Menichini, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

Breast cancer; Mutant p53; Nucleolus; P53 degradation; P53 ubiquitylation; PRIMA 1

Indexed keywords

CHEMICAL COMPOUND; DOXORUBICIN; MUTANT PROTEIN; PRIMA 1; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CORRELATIONAL STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78149431656     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.031     Document Type: Article

References (30)

1. Soussi T., Lozano G. P53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. 2005, 331:834-842.
2. Harris S.L., Levine A.J. The P53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
3. Peng Y., Li C., Chen L., Sebti S., Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003, 22:4478-4487.
4. Bykov V.J., Issaeva N., Selivanova G., Wiman K.G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the national cancer institute database. Carcinogenesis 2002, 23:2011-2018.
5. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumour suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
6. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., Selivanova G. Rescue of mutants of the tumour suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA 2003, 100:13303-13307.
7. Selivanova G., Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26:2243-2254.
8. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
9. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
10. Liang Y., Besch-Williford C., Benakanakere I., Hyder S.M. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Int. J. Oncol. 2007, 31:777-784.
11. Liang Y., Besch-Williford C., Hyder S.M. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int. J. Oncol. 2009, 35:1015-1023.
12. Shen J., Vakifahmetoglu H., Stridh H., Zhivotovsky B., Wiman K.G. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008, 27:6571-6580.
13. Chipuk J.E., Maurer U., Green D.R., Schuler M. Pharmacologic activation of p53 elicits bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4:371-381.
14. Supiot S., Zhao H., Wiman K., Hill R.P., Bristow R.G. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother. Oncol. 2008, 86:407-411.
15. Lambert J.M., Gorzov P., Veprintsev D.B., Soderqvist M., Segerback D., Bergman J., Fersht A.R., Hainaut P., Wiman K.G., Bykov V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15:376-388.
16. Rökaeus N., Klein G., Wiman K.G., Szekely L., Mattsson K. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene 2007, 26:982-992.
17. Ruggero D., Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 2003, 3:179-192.
18. Rubbi C.P., Milner J. Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. Oncogene 2000, 19:85-96.
19. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO. J. 2003, 22:6068-6077.
20. Wsierska-Gadek J., Horky M. How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-activation. Ann. NY. Acad. Sci. 2003, 1010:266-272.
21. Karni-Schmidt O., Friedler A., Zupnick A., McKinney K., Mattia M., Beckerman R., Bouvet P., Sheetz M., Fersht A., Prives C. Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene 2007, 26:3878-3891.
22. Karni-Schmidt O., Zupnick A., Castillo M., Ahmed A., Matos T., Bouvet P., Cordon-Cardo C., Prives C. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J. Cell. Sci. 2008, 121:4098-4105.
23. Bartek J., Iggo R., Gannon J., Lane D.P. Genetic, immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990, 5:893-899.
24. Magrini R., Russo D., Ottaggio L., Fronza G., Inga A., Menichini P. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J. Cell. Biochem. 2008, 104:2363-2373.
25. Becker K., Marchenko N.D., Maurice M., Moll U.M. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 2007, 14:1350-1360.
26. Midgley C.A., Lane D.P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997, 15:1179-1189.
27. Lukashchuk N., Vousden K.H. Ubiquitination and degradation of mutant p53. Mol. Cell. Biol. 2007, 27:8284-8295.
28. Muller P., Hrstka R., Coomber D., Lane D.P., Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27:3371-3383.
29. Zimber A., Nguyen Q.D., Gespach C. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. Cell Signal. 2004, 16:1085-1104.
30. Shi H., Lambert J.M., Hautefeuille A., Bykov V.J., Wiman K.G., Hainaut P., de Fromentel C.C. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008, 29:1428-1434.